Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GBP-213
- Development stage
- Phase 1
- Lead developer
- Renji Hospital
- Administration
- Subcutaneous
01
Overview
GBP-213 is an investigational therapeutic agent being developed by Renji Hospital for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It is administered via subcutaneous injection. In late 2026, the drug entered an Early Phase 1 clinical trial in China to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with rapidly progressive ADPKD. The exact molecular target and modality of GBP-213 have not been publicly disclosed.
Beyond the preview
Go deeper on GBP-213.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GBP-213.